Telix Pharmaceuticals Lim... (TLX)
Telix Pharmaceuticals Limited (TLX) Stock Price, Analysis & Data
| Precio de compra | 11.78 |
| Capitalización de mercado | 4.11B |
| Ingresos (TTM) | 803.79M |
| Beneficio neto (TTM) | -7.13M |
| Beta | 0.60 |
| EPS (TTM) | -0.02 |
| Ratio PER (TTM) | n/a |
| Adelante PE | 85.23 |
| P/B (TTM) | 9.89 |
| P/S (TTM) | 5.11 |
| Earnings Date | n/a |
| Precio de venta | 10.32 |
| Volumen | 42,691 |
| Volumen medio (20D) | 158,151 |
| Abierto | 11.87 |
| Anterior Cerrar | 11.73 |
| Rango del día | 11.84 - 11.98 |
| Rango de 52 semanas | 6.28 - 12.60 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with adv...
Desempeño financiero
En 2025, los ingresos de Telix Pharmaceuticals fueron 803.79M, un aumento de 55.61% en comparación con 516.55M del año anterior. Las ganancias fueron -7.13M, una disminución de -121.15%.
Estados financieros
2 semanas hace · Simply Wall St.
Why Regeneron (REGN) Is Up 6.7% After Mixed Q2 Results And New Telix Oncology DealRegeneron Pharmaceuticals reported past second-quarter 2026 results with revenue rising to US$4,290.7 million from US$3,675.6 million a year earlier, while net income slipped to US$1,296.9 million and...
